Dr Matteo Lambertini meets with ecancer at SABCS 2017 to discuss the safety and effects on fertility of temporary ovarian suppression during breast cancer treatment with gonadotrophin releasing hormone (GnRH) analogues.

Looking at data from 5 European trials, Dr Lambertini outlines the safety and lasting fertility of the total patient populations, half of whom received GRH alongside their cancer treatments.

With improved fertility and ovarian function, as well as equal safety and overall survival scores, Dr Lambertini recommends this as a treatment option for all young breast cancer patients concerned with their later ovarian function.

Watch the press conference for more.